2023, Sep, 14;24(18):14108
So researchers are testing lower starting doses and ramping up more slowly
Researchers continue monitoring these effects to understand their severity, duration and impact on quality of life
Effect of empagliflozin on left ventricular mass in patients with type 2 diabetes mellitus and coronary artery disease: the EMPA-HEART Cardiolink-6 Randomized Clinical Trial
Why does Retatrutide appear, in some research contexts, to be associated with stronger reward blunting compared to Tirzepatide
We do not offer medical advice, we do not dispense medicines, and we do not promote any product for the diagnosis, treatment, cure, or prevention of any disease or condition in humans or animals